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Abstract
Background: Recently, increased plasma homocys-
teine (Hcy) has been suggested as an independent
risk factor for osteoporotic fractures. Therefore, it is
tempting to speculate that Hcy adversely affects bone
metabolism. This study aimed to analyze the relation
between Hcy and biochemical markers of bone
metabolism and bone mineral density (BMD). Mate-
rials and methods: We investigated 143 peri- and
post-menopausal women wmedian age (25th–75th
percentile), 67 (57–75) yearsx. All subjects underwent
a detailed medical examination, measurement of
bone mineral density at lumbar spine (BMD-LS) and
total hip (BMD-HIP), and fasting venous blood and
urine sampling. Osteocalcin (OC), serum calcium (Ca),
urinary desoxypyridinoline cross-links (DPD), osteo-
protegerin (OPG) and soluble receptor activator of NF-
kB ligand (sRANKL) were studied. Results: According
to BMD subjects were classified as normal (ns24),
osteopenic (ns51) or osteoporotic (ns68). Median
Hcy did not differ between normal, osteopenic and
osteoporotic subjects (ps0.647). Partial correlation
analysis, controlling for the major confounders, age,
creatinine, menopause and previous fractures,
revealed significant correlations between Hcy and
DPD (rs0.193, ps0.022), as well as between Hcy and
Ca (rs0.170, ps0.045). After adjustment for the same
confounders, subsequent regression analysis con-
firmed significant associations of Hcy with DPD and
Ca. No significant relations could be observed
between Hcy and BMD-LS, BMD-HIP, OC, OPG or
sRANKL. Conclusion: Our results demonstrate weak,
but significant, relations between Hcy and markers of
organic and inorganic bone resorption, suggesting a
mechanistic role of Hcy in bone metabolism. The rela-
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tion between Hcy and bone resorption was not
dependent on OPG or sRANKL.
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Introduction
Osteoporosis is a major public health problem, caus-
ing considerable morbidity and mortality (1–3). It has
been estimated that in a 10-year period, postmeno-
pausal white women in the US will experience 5.2 mil-
lion fractures of the hip, spine, or distal forearm,
which will lead to 2 million person-years of fracture-
related disability and to over $45 billion in direct med-
ical expenditure (4). A comparable situation is evident
in Europe (5, 6). Prevention of osteoporosis by iden-
tifying risk factors or risk indicators is therefore a
major issue. Previous studies found advancing age,
female gender, early menopause, low body weight,
cigarette smoking, alcohol consumption, low calcium
intake, a low physical activity level, tallness, prior low-
trauma fracture as an adult, and history of hip fracture
in a first-degree relative as important risk factors for
osteoporosis (7–9).
Recently, it has been suggested that an increased
plasma homocysteine (Hcy) level is an independent
risk factor for osteoporotic fractures in elderly per-
sons (10, 11). Moreover, Hcy-lowering therapy with
high doses of folate and vitamin B12 has been shown
to strongly reduce the hip fracture rate in stroke
patients (12). However, all these studies are of epi-
demiological nature, providing no information about
the mechanisms behind the relation between Hcy and
fracture risk.
Previous investigations reported no or only weak
associations between Hcy and bone mineral density
(BMD) (11, 13–15). Since BMD measurement detects
changes in bone metabolism with a significant delay
(16–18) and provides no or only poor information
about the microarchitecture of the bone matrix, these
findings are not surprising. On the contrary, markers
of bone resorption and formation have been pro-
posed as a tool for the early detection of changes in
bone metabolism (19, 20). Even if their clinical use is
still a matter of debate (19), these markers could be a
useful tool in demonstrating a relation between Hcy
and bone metabolism. At present, few data exist
regarding the relation between Hcy and biochemical
bone turnover markers (21–23). Moreover, nothing is
known about Hcy and the osteoprotegerin (OPG)/sol-
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Table 1 Summary of anthropometric data and risk factors for osteoporosis.
All subjects Normal BMD Osteopenia Osteoporosis
Number 143 24 51 68
Age, years 67 (57–75) 55 (50–67) 68 (60–70)* 71 (61–77)*
Weight, kg 60 (54–67) 64 (58–62) 63 (56–70) 58 (53–63)*§
Height, cm 161 (156–166) 163 (160–167) 161 (156–166) 160 (154–165)*
BMI 23 (21–26) 24 (21–29) 24 (22–26) 23 (21–25)
Peri-menopausal, n 16 12 3 10
Post-menopausal, n 127 12 48* 58*
Age at menopause, years 49 (45–50) 54 (47–56) 49 (48–51) 48 (45–50)
Previous fractures, n 37 1 3 33*§
Daily calcium intake, mg 769 (519–1049) 901 (621–1186) 651 (467–965) 844 (544 –1117)
Previous or current 0 0 0 0
vitamin use, n
Normal BMD, t-score at hip and lumbar spine )y1.5; osteopenic, BMD t-score at hip or lumbar spine between y1.5 and
y2.5); osteoporotic, BMD t-score at hip or lumbar spine -y2.5. * vs. normal subjects, vs. osteopenic subjects. Values are
given as median (25th–75th percentile).
uble receptor activator of NF-kB ligand (sRANKL) sys-
tem, which is centrally involved in activation and
differentiation of osteoclasts. Such data would pro-
vide a first indication of the existence of a mechanistic
link between Hcy and bone metabolism and would
help to clarify the role of hyperhomocysteinemia
(HHcy) in osteoporosis.
We hypothesized that plasma Hcy is related to
biochemical bone turnover markers and the OPG/
sRANKL system. Consequently, in this study we in-
vestigated Hcy, biochemical bone turnover markers,
OPG, sRANKL and BMD in peri- and post-menopausal
women.
Materials and methods
Study design
In this cross-sectional study we investigated 143 peri- and
post-menopausal women with a median (25th–75th per-
centile) age of 67 (57–75) years, a median height of 161
(156–166) cm and a median weight of 60 (54–67) kg, who
were occasionally recruited from an endocrinological clinic
in Basel, Switzerland. To cover the whole range of bone loss,
we selected individuals according to their BMD and tried to
include sufficient numbers of normal, osteopenic and osteo-
porotic individuals (Table 1). None of the subjects was diag-
nosed with abnormal BMD (t-score at hip or lumbar spine
-y1.5) prior to the study. Consequently, none of the sub-
jects was undergoing anti-osteoporotic treatment when
blood was sampled. Subjects were excluded if they used
pharmaceuticals known to interfere with bone metabolism
(e.g., corticosteroids, anti-osteoporotic drugs, B vitamins).
All women were interviewed and examined by the same
experienced endocrinologist, who was blinded to the Hcy
measurement. For each subject, a detailed medical history,
physical examination, BMD measurement at lumbar spine
and total hip, venous blood sampling (after overnight fast-
ing) and urine collection (first morning void) were carried
out. Blood levels of Hcy, osteocalcin (OC), calcium (Ca) and
creatinine, as well as urine levels of desoxypyridinoline
cross-links (DPD) were measured. In addition, in a subset of
89 individuals, OPG and sRANKL were determined. Daily cal-
cium intake was anamnestically assessed, and estimated on
the basis of supplement use and milk consumption. Patient
characteristics are summarized in Table 1. The study was
conducted in accordance with the guidelines of the Decla-
ration of Helsinki and was approved by the institutional
Review Board.
BMD measurement
BMD at lumbar spine (BMD-LS) and hip (BMD-HIP) was eval-
uated by dual X-ray absorptiometry (DXA) using a Lunar
Expert densitometer (24) (GE Healthcare, Freiburg, Germa-
ny). Lumbar vertebrae with prevalent or incident fractures at
L1–L4 were not included in the BMD measurement. BMD
was expressed as g/cm2 of hydroxyapatite and as t-score for
the respective anatomical site according to the European ref-
erence database of the Lunar Expert device.
Pre-analytical sample handling
Fasting venous blood samples were drawn during the office
visits between 08:00 and 10:00 h. Samples were allowed to
clot for 30 min before serum was separated from cellular
blood components by centrifugation. Urine samples were
obtained from the first morning void. Serum and urine
samples were stored at y208C until analysis.
Laboratory analysis
Hcy was measured on an ADVIA CENTAUR automated
analyzer (Bayer Diagnostics, Fernwald, Germany) using a
commercial chemiluminescence immunoassay (Bayer Diag-
nostics). Intra- and inter-assay CVs were F5.2%. OC was
detected with a commercial chemiluminescence immuno-
assay (Roche Diagnostics, Mannheim, Germany) on an Elec-
sys 2010 automated analyzer (Roche Diagnostics). Intra- and
inter-assay CVs were F7.2%. Creatinine and calcium were
measured using methods from Roche Diagnostics on a Hita-
chi 917 analyzer (Roche Diagnostics). OPG and sRANKLwere
analyzed by ELISA (Immundiagnostik, Bensheim, Germany).
Intra- and inter-assay imprecision were F9.0% for sRANKL
and F10% for OPG.
Urine DPD was measured with the Crosslinks assay
(BioRAD, Munich, Germany) by high-performance liquid
chromatography (HPLC) and the results are expressed in
relation to urinary creatinine. The detection limit was
5.0 pmol/L, with a reference range of 9–20 pmol/mmol DPD/
creatinine. Urinary creatinine was assayed on a Hitachi 917
automated analyzer using a method from Roche Diagnostics.
For quality control we used the appropriate quality control
materials provided by the test manufacturers.
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Figure 1 Boxplot (25th–75th percentile) showing the medi-
an Hcy (mmol/L) concentration in normal (BMD t-score at hip
and lumbar spine)y1.5), osteopenic (BMD t-score at hip or
lumbar spine between y1.5 and y2.5) and osteoporotic
(BMD t-score at hip or lumbar spine -y2.5) subjects. The
dashed line shows Hcy cut-off of 12 mmol/L.
Figure 2 Partial correlation analysis between log Hcy and DPD and serum calcium, controlling for age, creatinine (creat),
menopause, and previous fractures.
Statistical analysis
First we performed a Kolmogorov-Smirnov test to check all
variables for normality. Since several variables were not dis-
tributed normally, we report the descriptive statistics as
median (25th–75th percentile). Medians were compared
using a Mann-Whitney U-test. If more than two medians
were compared, we used a Kruskal-Wallis test. First, we ana-
lyzed median Hcy levels in relation to diagnostic groups
according to BMD (see Results). Subsequently, we per-
formed a partial correlation analysis, controlling for the
major confounders, age, creatinine, menopausal status (peri-
or post-menopausal) and previous fractures. Since Hcy was
not distributed normally (ps0.005, Kolmogorov-Smirnov
test), we log-transformed Hcy (log Hcy) prior to correlation
analysis. Variables that were significantly correlated to log
Hcy were then used as independent variables in a linear
regression analysis, adjusting for the major confounders,
age, creatinine, menopause and previous fractures. A value
of p-0.05 was considered as significant. Calculations were
carried out with the software package SPSS (version 11.0 for
Windows; SPSS Inc., Chicago, IL, USA).
Results
According to BMD measurement, subjects were clas-
sified as normal (t-score at lumbar spine and hip
)y1.5; ns24), osteopenic (t-score at lumbar spine or
hip between y1.5 and y2.5; ns51) or osteoporotic (t-
score at lumbar spine or hip -y2.5; ns68). The per-
centage of peri-menopausal women was highest in
subjects with normal BMD (Table 1). As expected,
median age increased with decreasing BMD. Further-
more, median weight and height decreased with
decreasing BMD. Previous fractures were reported
more frequently in osteoporotic than in osteopenic or
normal women (Table 1).
Median Hcy did not differ between normal, osteo-
penic and osteoporotic individuals (ps0.647; Figure
1). Moreover, partial correlation analysis controlling
for age, creatinine, previous fractures, and meno-
pause did not reveal significant correlations between
log Hcy and BMD-HIP (rs0.104, ps0.234) and BMD-
LS (rs0.157, ps0.070).
For the biochemical bone turnover markers, partial
correlation analysis controlling for age, creatinine,
previous fractures, and menopause revealed a signif-
icant relation between log Hcy and DPD (rs0.193,
ps0.022; Figure 2). Serum Ca, which is mainly
released from the inorganic bone matrix, was also
correlated to log Hcy (rs0.170, ps0.045; Figure 2). In
contrast, OC, OPG and sRANKL exhibited no associ-
ation with log Hcy. The adjusted regression model
confirmed that log Hcy was independently related to
DPD and Ca (Table 2).
Discussion
The main finding of this study is a weak, but signifi-
cant, relation between Hcy and the bone resorption
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Table 2 Regression analysis using DPD and Ca as dependent variables and log Hcy as independent variable.
Dependent Adjusted for b p
variable
DPD Raw 5.33 0.105
Age, creatinine, previous fractures, menopause 8.22 0.022*
Previous fractures, menopause, creatinine 7.33 0.029*
Previous fractures, creatinine 6.22 0.050*
Ca Raw 0.12 0.037*
Age, creatinine, previous fractures, menopause 0.13 0.045*
Age, previous fractures, creatinine 0.13 0.037*
Age, previous fractures 0.14 0.017*
Age 0.12 0.037*
b- and p-values are presented for the raw model, as well as for several adjusted models, including the major confounders,
age, creatinine, menopause and previous fractures. BMD-LS, bone mineral density at lumbar spine; DPD, urine cross-links;
Ca, serum calcium. *p-0.05.
marker DPD, suggesting a mechanistic link between
Hcy and bone metabolism. This hypothesis is sup-
ported by the association between Hcy and serum Ca.
Contrary to DPD and Ca, the bone formation marker
OC and BMD at lumbar spine or hip were not asso-
ciated with Hcy. Furthermore, higher DPD and Ca lev-
els in the presence of elevated serum Hcy were not
accompanied by differences in OPG or sRANKL, two
central regulators of the equilibrium between osteo-
blasts and osteoclasts.
Osteoporosis is mainly diagnosed by BMD meas-
urement and anamnestic data (25). In our sample, Hcy
was not related to BMD-LS and BMD-HIP. This finding
is in accordance with previous studies (11, 13–15)
showing no or only a weak association of Hcy and
BMD. However, the lack of correlation between Hcy
and BMD is not surprising, since BMD mainly reflects
bone mineralization and provides only an integral
measure of bone metabolism over time (16–18, 26).
BMD does not reflect the current status of bone
metabolism and presents only poor information
about the microarchitecture of bone matrix.
Biochemical markers of bone resorption and for-
mation have been proposed as a tool for the early
detection of changes in bone metabolism (19, 20) and
might be more suitable for detecting the effects of Hcy
on bone metabolism than BMD. The present study
revealed weak, but significant, correlations between
Hcy and the bone resorption marker DPD, as well as
between Hcy and Ca (representing resorption of inor-
ganic bone matrix), but no correlation between Hcy
and the bone formation marker OC. These findings
were still significant after adjustment for the major
confounders, age, renal function, menopause and
previous fractures, suggesting an association
between Hcy and bone resorption activity. The rela-
tion between Hcy and DPD is in agreement with pre-
vious findings by others (21–23). Bode et al. reported
a relation with comparable strength between Hcy and
collagen I C-terminal cross-links, another well-estab-
lished bone resorption marker, in patients with coro-
nary artery disease (21). Miyao et al. found higher
DPD levels in 57 subjects with a homozygous MTHFR
C677T genotype, which is known to be associated
with higher Hcy levels (22). Unfortunately, they did
not measure Hcy, which limits the comparability with
our results. Recent data from the Longitudinal Aging
Study Amsterdam (LASA) confirmed a significant cor-
relation between Hcy, vitamin B12 and DPD in 615
men and 652 women (23). Contrary to our results, a
positive relation between Hcy and OC was also
observed. However, a relation between Hcy and DPD
and OC was only detectable in the presence of low
vitamin B12 levels, indicating an important mechanis-
tic role of vitamin B12 in bone metabolism.
In the study presented here, and in all of the above-
mentioned publications, the strength of the relations
observed between Hcy and DPD, OC and Ca was
relatively weak, suggesting that these results can
probably not explain the impressive clinical results
observed by others previously (10–12). McLean et al.
demonstrated a notable increase in fracture risk at
Hcy levels between 14 and 19 mmol/L (10). Based on
our results, an increase from 10 to 15 mmol/L would
only cause a marginal increase in DPD of approxi-
mately 1.5 pmol/mmol. Similar results were found in
all other studies reported (21–23). In view of the dis-
crepancy between our results and the clinical data, it
can be speculated that the stimulation of bone matrix
degradation by Hcy is of limited clinical relevance and
that use of the currently available bone turnover
markers is not appropriate for monitoring the bio-
chemical effects of Hcy or B-vitamin deficiencies on
bone metabolism.
In patients with homocystinuria, characterized by
extremely high Hcy levels and an increased preva-
lence of skeletal deformities, including osteoporosis
(27–29), McKusick (30) proposed a disturbed cross-
linking of collagen, which has been supported by two
later studies (31, 32). Lubec et al. observed lower
collagen I C-terminal telopeptide (ICTP) levels in 10
patients with homocystinuria, concluding that this
would indicate disturbed collagen I cross-linking (32).
However, the majority of the existing bone resorption
markers, including DPD, measure the breakdown of
collagen I (17) and detect constituents of the non-hel-
ical N- or C-terminal telopeptides, or the cross-linking
molecules of collagen I. Based on clinical and analyt-
ical experience, DPD is currently considered the best
marker for the assessment of bone resorption (21, 17).
Contrary to bone resorption markers, OC is a small
hydroxyapatite-binding protein mainly synthesized by
osteoblasts (17). It is therefore considered as a rela-
tive specific marker of osteoblast function (17). How-
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ever, none of the existing biochemical bone turnover
markers has been shown to provide information
about the microstructure of bone matrix (e.g., cross-
linking of collagen molecules, integration of collagen
molecules in bone matrix, interconnection of spongy
trabeculae), which is probably crucial for mechanical
stability. Due to the severe limitations of the few stud-
ies available, McKusick’s hypothesis of disturbed
collagen cross-linking has to be considered as not
proven. Moreover, it is not clear whether findings in
patients with homocystinuria are directly applicable
to normal Hcy variations among adults.
Nevertheless, together with existing studies, the
present study provides a clear indication of the exis-
tence of a mechanistic role of Hcy in bone meta-
bolism, and in particular in bone resorption. This
conclusion is supported by cell culture experiments
with human osteoclasts showing a dose-dependent
increase in osteoclast activity with increasing Hcy
concentrations in the culture medium (33).
OPG and sRANKL are central regulators of the equi-
librium between osteoclast and osteoblast activity
(34–37). In this study we did not observe an associa-
tion between Hcy and OPG or sRANKL, indicating that
Hcy does not affect bone metabolism by the OPG/
sRANKL system. However, the significance of this
finding is limited by the relatively low sensitivity of
the existing first-generation OPG and sRANKL immu-
noassays. Future studies should focus on free s-
RANKL, which possibly better detects modified
OPG-binding capacity.
In conclusion, the present study demonstrates a
weak relation between Hcy and the bone resorption
marker DPD, as well as between Hcy and serum Ca,
suggesting a mechanistic link between Hcy and bone
metabolism. However, the associations observed
were not strong enough to explain the known relation
between Hcy and fracture risk, and could not be sup-
ported by other biochemical markers of bone metab-
olism, such as OC, OPG or sRANKL. Therefore, future
studies are needed to provide more insight into the
mechanistic role of Hcy in osteoporosis as a useful
paradigm with interesting therapeutic implications,
because Hcy-lowering therapy could favorably influ-
ence the disease course in osteoporotic patients.
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